JP2021147380A - Antioxidant composition - Google Patents

Abstract

To provide novel antioxidant compositions containing a natural product or a primary processed product thereof as an active ingredient.MEANS FOR SOLVING THE PROBLEM: Provided is an antioxidant composition containing a fermented milk product of Lactobacillus kefiri or a processed product thereof as an active ingredient. This antioxidant composition can be used to reduce oxidative stress. Further, the Lactobacillus kefiri is preferably Lactobacillus Kefiri P-IF (accession number FERM BP-10896).SELECTED DRAWING: None

Description

The present invention relates to antioxidant compositions.

Oxidative stress is involved in the aging process, which is said to be closely related to the formation of reactive oxygen species (ROS). These reactive oxygen species (ROS) are highly reactive and can oxidatively damage many biopolymers such as nucleic acids, proteins and lipids, which can lead to genetic variation and cellular senescence. be.

Higher levels of free radicals have been reported in aged rats. This is due to lower antioxidant levels. Age-dependent reductions in antioxidant levels have been well demonstrated in rats and humans. For example, mRNA levels of enzymatic antioxidants such as superoxide dismutase, catalase and glutathione peroxidase have been quantified and found to be reduced in the liver of aged rats.

The redox state of cells that changes during aging may be altered by diet. Iron and other undernourishments, which currently affect more than 2 billion people worldwide, have been shown to induce oxidative stress. Previous studies suggest that ferritin acts as a protective agent against oxidative damage to endothelial cells as well as mouse and human leukemia cells. We have recently shown that the antioxidant effect of iron-based hydroferrate fluids derived from divalent and trivalent ferrates exhibits a protective effect on oxidative stress-induced apoptosis of mouse splenocytes in vitro. (Non-Patent Document 1).

Lactic acid bacteria, on the other hand, are another natural diet-related substance that has long been thought to have the potential to extend human lifespan. Biologist Eli Metchnikoff suggested this effect in the early 1900s (Non-Patent Document 2). Lactic acid bacteria are often used in the production of fermented milk and foods, and the lactic acid bacteria strain contained in fermented milk is a normal bacterium found in the intestinal flora. Lactic acid bacteria have been shown to help reduce intestinal pathogens while maintaining a healthy balance of probiotic bacteria. In addition, lactic acid bacteria have been shown to have beneficial effects on a variety of diseases, including rheumatoid arthritis, Crohn's disease, and cancer.

Badr El-Din NK, Noaman E, Fattah SM, Ghoneum M. Reversal of age-associated oxidative stress in rats by MRN-100, a hydro-ferrate fluid. In Vivo. 2010; 24 (4): 525-33. Metchinkoff E and Metchinkoff II: The Prolongation of Life: Optimistic Studies. Putnam, New York, NY, pp109-132, 1908.

If new active ingredients of antioxidant compositions can be provided, the range of treatment and treatment options will be expanded. Further, if the natural product or its primary processed product is an active ingredient, the risk of side effects is considered to be low, which is desirable.

Therefore, an object of the present invention is to provide a novel antioxidant composition containing a natural product or a primary processed product thereof as an active ingredient.

The present inventors have diligently studied in order to achieve the above object, and have completed the present invention. That is, the present invention is as follows.
[1] An antioxidant composition containing a fermented milk product of Lactobacillus kefiri or a processed product thereof as an active ingredient.
[2] The antioxidant composition according to [1], which is used to reduce oxidative stress.
[3] The antioxidant used according to [1] or [2], wherein the Lactobacillus kefiri includes Lactobacillus Kefiri P-IF (accession number FERM BP-10896). Composition.

According to the present invention, since the milk fermented product of Lactobacillus kefiri or a processed product thereof is used as an active ingredient, a novel antioxidant composition capable of obtaining a safe and antioxidant effect with few side effects is provided. can do.

It is a chart showing the result of evaluating the biochemical serum parameters in Test Example 6, and FIG. 1 (a) is the chart showing the result of measuring the enzyme activity of ALT (EC 2.6.1.2) in serum. 1 (b) is a chart showing the results of measuring the enzyme activity of AST (EC 2.6.1.1) in serum, and FIG. 1 (c) is a chart showing the concentration of total protein in serum. It is a chart which shows the result of this. FIG. 2A is a chart showing the results of evaluation of biochemical serum parameters in Test Example 6, and FIG. 2A is a chart showing the results of measuring the concentration of total cholesterol (TC) in serum, and FIG. 2 (a). b) is a chart showing the result of measuring the concentration of triglyceride (TG) in serum, and FIG. 2 (c) is a chart showing the result of measuring the concentration of low-density lipoprotein (LDL) in serum. FIG. 2D is a chart showing the results of measuring the concentration of high-density lipoprotein (HDL) in serum.

The Lactobacillus kefiri may be a microorganism belonging to Lactobacillus kefiri, and is not particularly limited, but is preferably Lactobacillus Kefiri P-IF (accession number FERM). BP-10896) is used. Lactobacillus kefiri can be cultured by a known method or according to it, and is anaerobically allowed to stand using, for example, a commercially available MRS medium (trade name "Lactobacilli MRS Broth", manufactured by Difco). Mass culture is possible by culturing.

A milk fermented product of Lactobacillus kefiri can be obtained by inoculating a dairy raw material with Lactobacillus kefiri as a starter and exposing it to predetermined fermentation conditions.

Milk raw materials for milk fermentation include, for example, milk, milk boiled milk, fermented milk, lactic acid bacteria beverage, defatted milk, defatted powdered milk, prepared powdered milk, whole fat powdered milk, concentrated milk, defatted concentrated milk, condensed milk, defatted condensed milk, sweetened condensed milk. , Sweetened defatted condensed milk and the like. These can be used as raw materials for milk fermentation as they are, or after being appropriately dissolved, diluted, or concentrated in water or the like, and then subjected to a treatment such as autoclave sterilization as necessary.

Examples of the method for inoculating the fermentation microorganism (starter) include a method of adding a pre-culture solution using an MRS medium or the like, and a method of adding the remaining milk fermented product from the previous fermentation. As the culture conditions, a method of anaerobically standing culture at 20 to 30 ° C., more preferably 24 to 26 ° C. for 1 to 10 days, more preferably 3 to 7 days is preferably adopted.

As the starter of the milk fermentation, a plurality of bacterial species may be used in combination. According to this, since milk fermentation occurs by the symbiotic growth of a plurality of microorganisms, a milk fermented product having a good taste and appearance can be obtained. For example, at least one yeast selected from the group consisting of Kazachstania turicensis, Kazachstania unispora, and Kluyveromyces marxianus may be used in combination. Alternatively, as Lactobacillus kefiri, in addition to the above-mentioned Lactobacillus Kefiri P-IF (accession number FERM BP-10896), Lactobacillus kefiri P-B1 (Lactobacillus kefiri P-B1) ( The accession number FERM BP-11115) may be used together.

In a particularly preferred embodiment, as the starter of the milk fermentation, Lactobacillus kefiri P-IF (accession number FERM BP-10896) is used as a main microorganism, and Lactobacillus kefiri P is used as a secondary microorganism. -B1 (Lactobacillus kefiri P-B1) (accession number FERM BP-11115), Kazachstania turicensis P-Y3 (accession number FERM BP-11116), Kazachstania unispora P-Y4 (Kazachstania unispora P-Y4) ) (Commissioned number FERM BP-11117) and Kluyveromyces marxianus P-Y5 (Commissioned number FERM BP-11118) Lactobacillus kefiri P-IF (accession number FERM BP-10896) occupies 80% or more, more preferably 90% or more in the microbial community of the later milk fermented product. It is preferred to prepare and use the milk fermented product so prepared.

In the present invention, the milk fermented product of Lactobacillus kefiri obtained as described above or a processed product thereof is used as the active ingredient of the antioxidant composition. Here, the "processed product" includes heat sterilization, concentration, drying, separation of bacterial cells, removal of bacterial cells, crushing of bacterial cells, dilution with an aqueous solvent, a hydroalcoholic solvent, etc., and an aqueous solvent. Includes those prepared by performing one or a combination of two or more treatments such as extraction into a hydroalcoholic solvent or the like. In addition, extracts prepared by subjecting an extract extracted with an aqueous solvent or a hydroalcoholic solvent to one or a combination of two or more treatments such as heat sterilization, concentration, drying, and removal of solids are also included. ..

For example, Lactobacillus kefiri is killed by subjecting its cells to a heat treatment at 60 to 120 ° C, more preferably 95 to 120 ° C. Therefore, the fermented milk product can be pulverized by spray drying, but it may be killed by the heat added at the same time. Alternatively, the milk fermented product may be pulverized by freeze-drying. According to this, it is also possible to provide Lactobacillus kefiri in a living state by reconstitution of the freeze-dried milk fermented product with water or the like.

In the antioxidant composition of the present invention, there is no particular limitation on blending other materials other than the above active ingredients, and if necessary, a pharmaceutically acceptable base material or carrier is added. It can be used in the form of tablets, granules, capsules, pills, powders, liquids, powders, jelly-like agents, candy-like agents, injections, suction agents, coating agents and the like by a known formulation method. can.

The antioxidant composition of the present invention may be administered to humans or animals, and the administration form thereof is not particularly limited. For example, oral administration, intravenous administration, local administration in the brain, intraperitoneal administration, aspiration, nasal administration and the like can be mentioned. In particular, the oral administration form is preferable from the viewpoint of reducing the burden on the ingestor and easiness of taking.

When the antioxidant composition of the present invention is orally administered, the daily dose thereof is 0.01 (Lactobacillus kefiri) converted to the amount of the dried product of the milk fermented product (0.01). It is preferably g / kg body weight) to 10 (g / kg body weight), more preferably 0.05 (g / kg body weight) to 5 (g / kg body weight), and 0.1 (g / kg body weight). Body weight) to 1 (g / kg body weight) is even more preferred. Alternatively, the amount converted into the number of the kefili bacteria contained in the milk fermented product of Lactobacillus kefiri is 1 × 10 ¹³ (pieces / kg body weight) to 1 × 10 ¹⁶ (pieces / kg body weight). It is preferably 5 × 10 ¹³ (pieces / kg body weight) to 5 × 10 ¹⁵ (pieces / kg body weight), more preferably 1 × 10 ¹⁴ (pieces / kg body weight) to 1 × 10 ¹⁵ (pieces / kg body weight). / Kg body weight) is even more preferable. If the dose is less than those ranges, it is difficult to obtain a sufficient effect, and if the dose is higher than that range, the risk of causing some side effects increases.

The number of the kefir bacteria contained in the dried product of the milk fermented product of Lactobacillus kefiri shall be 5 × 10 ¹² (pieces / g) to 3 × 10 ¹⁵ (pieces / g). Is preferable, and 5 × 10 ¹³ (pieces / g) to 2 × 10 ¹⁵ (pieces / g) is more preferable, and 5 × 10 ¹⁴ (pieces / g) to 1 × 10 ¹⁵ (pieces / g). Is even more preferable.

The antioxidant composition of the present invention can be preferably used, for example, for improving oxidative stress with age. Typically, for example, for the improvement of age-related oxidative stress in humans, eg, 30 years or older, more typically 40 years or older, even more typically 50 years or older, most typically 60 years or older. It can be preferably used. In addition, it may be applied to pet animals and the like, and in particular, it can be preferably used for improving the oxidative strain associated with the age of elderly pet animals and the like corresponding to the human age. For example, in the case of dogs, for the improvement of oxidative stress associated with the age of dogs over 4 years old, more typically over 6 years old, even more typically over 8 years old, most typically over 10 years old. , Can be preferably used. Also, for example, in the case of cats, improvement of oxidative stress associated with the age of cats of 4 years or older, more typically 6 years or older, even more typically 9 years or older, and most typically 11 years or older. Therefore, it can be preferably used.

The form of the product for administering the antioxidant composition of the present invention is not particularly limited as long as its action and effect are not impaired. For example, it can be used in various product forms such as pharmaceuticals, quasi-drugs, health foods, functional foods, dietary supplements, supplements, etc., or in combination with these products. Alternatively, it may be an animal product for pet animals and the like.

The present invention will be specifically described below with reference to examples, but these examples do not limit the scope of the present invention.

[Materials and methods]
(1) Preparation of composition for antioxidant Lactobacillus kefiri P-IF (accession number FERM BP-10896) was inoculated into MRS liquid medium and pre-cultured at 25 ° C. As a major microorganism and other secondary microorganisms, Lactobacillus kefiri P-B1 (accession number FERM BP-11115), Kazachstania turicensis P-Y3 (accession number FERM) BP-11116), Kazachstania unispora P-Y4 (trust number FERM BP-11117), and Kluyveromyces marxianus P-Y5 (trust number FERM BP-11118) Using at least the complex microorganism contained as a starter, the cells were inoculated into a defatted milk medium (a medium prepared by mixing 90 parts by mass of ion-exchanged water with 10 parts by mass of defatted powdered milk and sterilizing by autoclave), and anaerobic at 25 ° C. for 5 days. It was statically cultured and fermented. The fermented culture obtained was a yellowish brown yogurt-like liquid in which Lactobacillus kefiri P-IF (accession number FERM BP-10896) accounted for more than 90% of the bacteria. This was heat-treated, freeze-dried, and used in the following animal experiments. The bacterial count concentration in the dried product was approximately 1 × 1015 / g. In addition, for the sake of brevity, this preparation will be referred to as "PFT" below.

(2) Animals and Experiments 10-month-old male Swiss albino mice (weight about 23-28 g: aged mice) and 2-month-old male Swiss albino mice (weight about 11-22 g: young mice) were used. Mice were classified into Group 1 (normal young mice), Group 2 (normal aged mice) and Group 3 (PFT treatment group). In the PFT-treated group, PFT was orally administered at a dose of 2 mg / kg body weight daily for 6 weeks with free water intake. Six weeks later, animals fasted overnight were anesthetized, blood was drawn from the abdominal aorta using a syringe, and serum was separated and stored at -80 ° C until analysis. In addition, the liver and brain tissue were rapidly excised, washed with ice-cooled 0.9% NaCl, frozen in liquid nitrogen, and stored at −80 ° C. in the same manner.

As a sample for analysis, tissues were homogenized with PBS, 0.1 M, pH 7.4 (9 mL / g tissue) and centrifuged at 4 ° C., 6000 rpm for 20 minutes and the supernatant was collected.

[Test Example 1]
<Evaluation of lipid peroxidation level and nitric oxide level>
Lipid peroxidation levels were assessed by analyzing malondialdehyde (MDA) content in the form of thiobarbituric acid-reactive material (TBARS). Specifically, a 500 μL sample was added to 1 mL of trichloroacetic acid (TCA, 15%) and centrifuged at 3000 rpm for 10 minutes. 1 mL of the supernatant was mixed with 500 μL of thiobarbituric acid (TBA, 0.7%), heated in a boiling water bath for 10 minutes, cooled and measured for absorbance with light of a wavelength of 532 nm. The TBARS level was calculated according to the following formula and calculated in units of the amount (nmol / mL) in the measurement sample dose (BROWN WD, TAPPEL AL "Fatty acid oxidation by carp liver mitochondria." Arch Biochem Biophys. 1959 Nov; 85: pp149-58.).

TBARS level (nmol / mL) = sample absorbance 532 nm / 156

Nitric oxide (NO) levels were measured using the grease reaction as follows. First, 100 μL of the sample was added to 100 μL of acidic grease reagent (containing 1% sulfanilamide and 0.1% naphthylethylenediamine dihydrochloride in 2.5% phosphoric acid), mixed, and then with light having a wavelength of 540 nm. The absorbance was measured. The NO level was determined in units of concentration (μM) in the measurement sample dose by separately creating standard curves over different concentrations using standard substances and applying the measurement results.

As shown in Table 1, the following (1) to (2) were clarified.
(1) TBARS level In aged mice, TBARS levels in liver, brain, and serum tissues were significantly increased as compared with young mice. In contrast, in the PFT-treated group, TBARS levels in each tissue were significantly reduced to 55% in the liver, 81% in the brain, and 73% in serum, as compared with the aged mice.

(2) NO level In aged mice, NO levels in liver, brain, and serum tissues were significantly increased as compared with young mice. In contrast, in the PFT-treated group, the NO level in each tissue was significantly reduced to 47% in the liver, 60% in the brain, and 82% in serum as compared with the aged mice.

From the above, it was clarified that the administration of PFT counteracted the increase in TBARS level and NO level related to age, in other words, it was clarified that oxidative stress was reduced by PFT.

[Test Example 2]
<Evaluation of reduced glutathione level and glutathione S-transferase activity>
Reduced glutathione (GSH) levels were measured as follows. First, a 100 μL sample was mixed with 100 μL of sulfosalicylic acid (4%). Then, it was held at 4 ° C. for at least 1 hour and centrifuged at 1200 rpm for 10 minutes at 4 ° C. 100 μL of supernatant was mixed with 2.7 mL phosphate buffer (0.1 M, pH 7.4) and 0.2 mL DTNB reagent (5,5'-Dithiobis (2-nitrobenzoic acid)) and incubated for 5 minutes. The absorbance of the yellow product was measured with light of a wavelength of 412 nm. The GSH level is the amount of protein in the measurement sample by separately creating standard curves over different concentrations using standard substances and applying the measurement results. It was determined in units of the amount (mg · mg-1 protein amount) with respect to.

Glutathione S-transferase (GST) activity was measured as follows using the binding of 1-chloro-2,4-dinitrobenzene (CDNB) to reduced glutathione (GSH). First, 100 μL of GSH (5 mM), 10 μL of CDNB (1 mM in ethanol) and 25 μL of sample were added to 1.365 mL of phosphate buffer (0.1 M, pH 6.5) and incubated for 20 minutes at room temperature. .. After that, the absorbance was measured with light having a wavelength of 310 nm, and the GST activity (μmol, min-1, mg-1 protein) was determined by a conventional formulation (Habig WH, Pabst MJ, Jakoby WB "Glutathione S-transferases". . The first absorbance step in mercapturic acid formation. ”J Biol Chem. 1974; 249: pp7130-39.).

As shown in Table 2, the following (1) to (2) were clarified.
(1) GSH level In aged mice, GSH levels in liver, brain, and serum tissues were significantly decreased as compared with young mice. In contrast, in the PFT-treated group, GSH levels in each tissue were significantly increased to 122% in the liver, 126% in the brain, and 167% in serum as compared with the aged mice.

(2) GST activity In aged mice, GST activity in liver, brain, and serum tissues was significantly reduced as compared with young mice. In contrast, in the PFT-treated group, GST activity in each tissue was significantly increased by 205% in the liver, 164% in the brain, and 255% in serum as compared with the aged mice.

From the above, it was clarified that the administration of PFT counteracts the increase in GSH level and GST activity related to age, in other words, it was clarified that PFT reduces oxidative stress.

[Test Example 3]
<Evaluation of superoxide dismutase activity, catalase activity, and glutathione peroxidase activity>
Superoxide dismutase (SOD) activity was measured as follows using the inhibition rate of pyrogallol oxidation. First, a test solution was prepared by adding 20 μL of a sample and 10 μL of 20 mM pyrogallol (10 mM hydrochloric acid aqueous solution) to 1 mL of a buffer solution. The absorbance of the test solution was measured after 30 seconds and 90 seconds with light having a wavelength of 420 nm. The inhibition rate of pyrogallol oxidation was calculated according to the following formula.

Inhibition rate (%) = [(100-ΔAt) / ΔAо] × 100
(ΔAt is the amount of change in absorbance 420n per unit time (1 minute) and unit dose (1 mL) of the test solution, and ΔAо is the amount of change in absorbance 420n per unit time (1 minute) and unit dose (1 mL) of the reference solution. )

For catalase (CAT) activity, 0.1 mL of sample is mixed with 0.5 mL of 0.2 M sodium phosphate buffer of pH 7.6 and 0.3 mL of 0.5% H2O2 in a sample cuvette, and the mixture is distilled. Dilute with water to give a total of 3 mL. The decomposition of H2O2 was measured by the absorbance of light having a wavelength of 240 nm, and the rate of change in absorbance per minute (absorbance rate of change% · min-1) was calculated as the enzymatic activity.

For glutathione peroxidase (GPx) activity, 50 μL of sample and 100 μL of GSH were added to 750 μL of Tris-HCl solution (50 mM, pH 7.6) and incubated at 37 oC for 10 minutes. Next, 1 mL of TCA (15% by mass) and 100 μL of H2O2 were added, and the mixture was centrifuged at 3000 rpm for 20 minutes. 1 mL of supernatant was added to 2 mL of Tris-HCl solution (0.4 M, pH 8.9) and 100 μL of DTNB reagent (5,5'-Dithiobis (2-nitrobenzoic acid)) and incubated for 5 minutes. The absorbance of the solution was measured with light having a wavelength of 412 nm, and the activity of GPx was calculated by the following formula.

GPx activity (mol, min-1, mg-1 protein amount) = (At-Ao) x 6.2 x [100 / 13.1] x 0.05 x 10
(At is the absorbance of the test solution at 412 nm, A0 is the absorbance of the reference solution at 412 nm)

As shown in Table 3, the following (1) to (3) were clarified.
(1) GPx activity In aged mice, GPx activity in liver, brain, and serum tissues was significantly decreased as compared with young mice. In contrast, in the PFT-treated group, GPx activity in each tissue was significantly increased by 136% in the liver, 142% in the brain, and 135% in serum as compared with the aged mice.

(2) CAT activity In aged mice, CAT activity in liver, brain, and serum tissues was significantly reduced as compared with young mice. In contrast, in the PFT-treated group, CAT activity in each tissue was significantly increased by 141% in the liver, 155% in the brain, and 140% in serum as compared with the aged mice.

(3) SOD activity In aged mice, SOD activity in liver, brain, and serum tissues was significantly reduced as compared with young mice. In contrast, in the PFT-treated group, SOD activity in each tissue was significantly increased to 289% in the liver, 170% in the brain, and 212% in serum as compared with the aged mice.

From the above, it was clarified that the decrease in GPx activity, CAT activity and SOD activity related to age was canceled by the administration of PFT, in other words, it was clarified that the oxidative stress was reduced by PFT.

[Test Example 4]
<Evaluation of total antioxidant capacity>
Total Antioxidant Capacity (TAC) levels were measured as follows. First, a 1 mL sample is added to a 1 mL solution containing sulfuric acid (0.6 M), sodium phosphate (28 mmol) and ammonium molybdate (4 mmol), the mixture is incubated at 95 ° C. for 90 minutes, cooled to room temperature and then cooled. The absorbance was measured with light having a wavelength of 695 nm. The TAC level was calculated according to the following formula.

TAC (%) = [(A0-At) / A0] × 100
(A0 is the absorbance of the reference solution at 695 nm, At is the absorbance of the test solution at 695 nm)

As shown in Table 4, aged mice had significantly reduced TAC levels in liver, brain, and serum tissues compared to young mice. In contrast, in the PFT-treated group, TAC levels in each tissue were significantly increased to 126% in the liver, 142% in the brain, and 144% in serum, as compared with the aged mice.

From the above, it was clarified that the administration of PFT canceled the decrease in TAC level related to age, in other words, it was clarified that oxidative stress was reduced by PFT.

[Test Example 5]
<Evaluation of anti-hydroxyl radical activity>
Anti-hydroxyl radical (AHR) activity was measured as follows. First, a 10 μL sample is added to the reaction product consisting of a mixture of 100 μL H2O2, 100 μL FeSO4, 100 μL 2-deoxyribose-D-ribose, and 2.7 mL phosphate buffer (pH 7.4). , 37 ° C. for 60 minutes. Then 0.2 mL of EDTA and 2 mL of TBA reagent (5.2 mL of perchloric acid, 1.5 g of thiobarbituric acid, 60 g of trichloroacetic acid) were added and the absorbance of the resulting pink complex was 532 nm. Measured with light of wavelength. The results were expressed in the unit of "(U ・ mg-1 protein amount)" by a conventional formula (Halliwell B1, Gutteridge JM, Aruoma OI "The deoxyribose method: a simple" test-tube "assay for determination of rate". constants for reactions of hydroxyl radicals. ”Anal Biochem. 1987; 165 (1): pp215-219.).

As shown in Table 5, aged mice had significantly reduced AHR activity in liver, brain, and serum tissues compared to young mice. In contrast, in the PFT-treated group, AHR activity in each tissue was significantly increased by 119% in the liver, 118% in the brain, and 119% in serum as compared with the aged mice.

From the above, it was clarified that the administration of PFT counteracts the decrease in AHR activity associated with age, in other words, it was clarified that PFT reduces oxidative stress.

[Test Example 6]
<Evaluation of biochemical serum parameters>
The enzyme activity of ALT (EC 2.6.1.2) and AST (EC 2.6.1.1), which are indicators of liver function, and the concentration of total protein were measured. In addition, the concentrations of total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) were measured as serum lipid profiles. These biochemical serum parameters were analyzed with a commercially available kit according to the kit manufacturer's instructions. In the test group, a PFT-treated group for aged mice and a PFT-treated group for young mice were provided, and sera were collected and used for analysis.

As a result, as shown in FIG. 1 (a), the serum concentration of ALT (EC 2.6.1.2), which is an index of liver function, was higher in the aged mice than in the young mice. In the PFT-treated group for aged mice, the concentration was reduced to the level of young mice.

In addition, as shown in FIG. 1 (b), the serum concentration of AST (EC 2.6.1.1), which is an index of liver function, was higher in the aged mice than in the young mice. In the PFT-treated group for aged mice, the concentration was significantly reduced.

In addition, as shown in FIG. 1 (c), there was no change in the concentration of total protein in serum between the test groups.

From the above, it was considered that the PFT treatment on the aged mice brought about an antioxidant effect on the liver and improved the liver function in the aged mice.

In addition, as shown in FIG. 2 (a), the serum concentration of total cholesterol (TC) was higher in the aged mice than in the young mice, whereas the concentration was higher in the PFT-treated group for the aged mice. It dropped to the level of young mice.

In addition, as shown in FIG. 2 (b), the serum concentration of triglyceride (TG) was higher in the aged mice than in the young mice, whereas the concentration was lower in the PFT-treated group for the aged mice. bottom.

In addition, as shown in FIG. 2 (c), the serum concentration of low-density lipoprotein (LDL) was higher in the aged mice than in the young mice, whereas in the PFT-treated group for the aged mice, the concentration was higher. The concentration dropped significantly.

In addition, as shown in FIG. 2 (d), the serum concentration of high-density lipoprotein (HDL) was lower in the aged mice than in the young mice, whereas in the PFT-treated group for the aged mice, the concentration was lower. Concentration increased to the level of young mice.

From the above, it was considered that the PFT treatment on the aged mice brought about an antioxidant effect on the liver, and the liver function in the aged mice was improved, so that the serum lipid profile was improved.

Although some embodiments of the present invention have been described above, these embodiments are shown as examples and are not intended to limit the scope of the invention. These novel embodiments can be implemented in various other embodiments, and various omissions, replacements, and changes can be made without departing from the gist of the invention. These embodiments and modifications thereof are included in the scope and gist of the invention, and are also included in the scope of the invention described in the claims and the equivalent scope thereof.

Claims (3)

An antioxidant composition containing a fermented milk product of Lactobacillus kefiri or a processed product thereof as an active ingredient. The antioxidant composition according to claim 1, which is used to reduce oxidative stress. The antioxidant composition according to claim 1 or 2, wherein the Lactobacillus kefiri is Lactobacillus Kefiri P-IF (accession number FERM BP-10896).

Images